ClinicalTrials.gg
RecruitingNCT06355232Updated Sep 17, 2025

Covid-19 and Influenza Oral Vaccine Study

A Phase 1 interventional study of Covid-19 vaccine and Influenza vaccine in covid19 Infection and Influenza, Human, sponsored by Vaxine Pty Ltd. Recruiting at 1 site in Australia. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-17.

Sponsored by Vaxine Pty Ltd · Phase 1, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as recruiting.
  • Started May 2024; still recruiting 2 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 89 studies in COVID-19 with a site in Australia — 6 open to participants now, 15 under way, 8 of them phase 3. COVID-19 · Australia.

Planned enrollment
46th of 79
100 · median 185
Started
2024
with 5 others
Phase 1
28 of 89
1 open now
Primary completion
2025-12
later than 7 of 14 live
Registered
85th of 89
by date
Lead sponsor
5 of 89
Vaxine Pty Ltd

Among the 89 studies in COVID-19 with a site in Australia, this one is the 46th largest by planned enrollment of the 79 interventional ones that give a count, is one of 6 that started in 2024, is one of 28 in phase 1, reaches primary completion later than 7 of the 14 other live ones, and was the 85th registered.

COVID-19

7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.

Browse COVID-19 studies →

Open to participants now

6 of the 89 studies in COVID-19 with a site in Australia are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 89 studies in COVID-19 with a site in Australia, or all of them as a file.
02

Study summary

The purpose of the current study is to assess the effectiveness of protein-based COVID-19 or influenza vaccines when given individually or together via oral/ sublingual mucosal route instead of intramuscular delivery. The comparator will be a seasonal influenza vaccine which will also be administered with Advax-CpG adjuvant via the oral route. This study will use a cross-over design and everyone in the study will over a space of about 4 months receive both the COVID-19 and influenza vaccines.

Read the detailed description

The SARS-CoV-2 outbreak has caused millions of deaths globally. It has a particularly high mortality rate in elderly people and those with chronic disease. SARS-COV-2 vaccines remain a key priority to help fight the current pandemic as they help reduce symptomatic infection and disease severity. However, vaccine immunity starts to wane as early as 3 months following the most recent immunisation. This rapidly waning vaccine immunity is a particular problem for the newer Omicron variants. Spikogen® vaccine is an Advax-CpG55.2 adjuvanted recombinant protein vaccine that was shown to significantly reduce infection and serious disease in a pivotal Phase 3 trial in 16,876 participants who received two intramuscular doses 3 weeks apart. SpikoGen® vaccine was licensed for use in the Middle East as a primary vaccine course in adults in October 2021. Eight million doses of SpikoGen® vaccine have subsequently been supplied to date. A booster study confirmed the safety and immunogenicity of SpikoGen® vaccine when given as a third dose intramuscular booster to adult participants who previously received two doses of either inactivated viral vaccine, adenoviral vector vaccine, mRNA or recombinant protein vaccine. While COVID-19 vaccines such as SpikoGen® vaccine have been shown to reduce the incidence of severe SARS-CoV-2 infection disease, they have less effect on SARS-CoV-2 infection or transmission. This is because intramuscular vaccines largely work by increasing antibody and T cell levels within the body, whereas what is needed to prevent infection and transmission is mucosal immunity, which means increasing immunity at the body surfaces where the virus initially gets access to the body, namely the mucosal surfaces of the nose and upper respiratory tract. To induce mucosal immunity normally requires immune cells at these respiratory tract surfaces to be exposed to the relevant viral antigen, which requires the vaccine to be applied to these surfaces in such a way as to trigger an appropriate immune response.The current study is based on the finding that an adjuvanted protein-based COVID-19 vaccine (SpikoGen®) when given as 2 sublingual doses 2 weeks apart in monkeys that had previously received a primary course of 2 intramuscular doses of the same vaccine, was safe and well tolerated and induced robust protection against challenge with the heterologous Omicron BA.5 virus. The monkeys that received the sublingual boost also showed reduced nasal virus shedding (additional details in the Investigator Brochure). This suggests an oral/ sublingual COVID-19 vaccine may also help block virus transmission. Similarly, mice that received sublingual inactivated influenza vaccine with Advax-CpG adjuvant have demonstrated robust protection against an otherwise lethal influenza infection. The purpose of the current study is to assess the effectiveness of protein-based COVID-19 or influenza vaccines when given individually or together via oral/ sublingual mucosal route instead of intramuscular delivery. The comparator will be a seasonal influenza vaccine which will also be administered with Advax-CpG adjuvant via the oral route. This study will use a cross-over design and everyone in the study will over a space of about 4 months receive both the COVID-19 and influenza vaccines.

03

Conditions studied

  • covid19 Infection
  • Influenza, Human

Keywords

  • covid-19
  • influenza
  • pandemic
  • mucosal
  • spikogen
  • advax
  • adjuvant
  • vaccine
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Able to provide written
  • Males or females 18 years of age or older
  • Understand and are likely to comply with planned study procedures and be available for all study visits.
  • Do not plan to have a non-study COVID-19 or influenza vaccine within the next 6 months.

Exclusion criteria

Exclusion Criteria:

  • Allergy to COVID-19 or seasonal influenza vaccine or one of its components e.g. polysorbate 80.
  • Have received a COVID-19 or influenza vaccine or an experimental agent within 30 days prior to the study vaccination or expect to receive another experimental agent or a COVID-19 or influenza vaccine during the trial reporting period.
  • Any serious medical, social or mental condition which, in the opinion of the investigator, would be detrimental to the subjects or the study.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Covid-19 vaccine group

    Subjects in this group will receive two sublingual doses of COVID-19 vaccine two weeks apart. Three months after the second dose they will receive two sublingual doses of influenza vaccine two weeks apart.

    Biological: Covid-19 vaccine · Biological: Influenza vaccine

  • Experimental
    Influenza vaccine group

    Subjects in this group will receive two sublingual doses of influenza vaccine two weeks apart. Three months after the second dose they will receive two sublingual doses of COVID-19 vaccine two weeks apart.

    Biological: Covid-19 vaccine · Biological: Influenza vaccine

  • Experimental
    Combined vaccine group

    Subjects in this group will receive two sublingual doses of combined COVID-19 and influenza vaccine two weeks apart. Three months after the second dose they will receive two sublingual doses of placebo vaccine two weeks apart.

    Biological: Covid-19 vaccine · Biological: Influenza vaccine

Interventions

  • BiologicalCovid-19 vaccine

    Recombinant SARS-CoV-2 spike protein with Advax-CpG55.2 adjuvant

    Also known as: SARS-CoV-2 vaccine

  • BiologicalInfluenza vaccine

    Inactivated seasonal influenza vaccine with Advax-CpG55.2 adjuvant

06

What researchers measure

Primary outcomes

  1. SARS-CoV-2 Seroconversion

    Proportion of study participants who seroconvert (4-fold or greater rise in serum spike antibody) by primary vaccine group

    Time frame: Between baseline and 2 weeks post the second dose

  2. Influenza Seroconversion

    Proportion of study participants who seroconvert (4-fold or greater rise in hemagglutinin antibody) by primary vaccine group

    Time frame: Between baseline and 2 weeks post the second dose

  3. SARS-CoV-2 Seroprotection

    Proportion of study participants who achieve a spike protein neutralisation titer of 32 or greater by primary vaccine group

    Time frame: Between baseline and 2 weeks post the second dose

  4. Influenza Seroprotection

    Proportion of study participants who achieve a hemagglutinin neutralisation titer of 40 or greater by primary vaccine group

    Time frame: Between baseline and 2 weeks post the second dose

  5. SARS-CoV-2 Geometric mean titer fold change

    Increase in Geometric mean titer of spike neutralisation antibodies by primary vaccine group

    Time frame: Between baseline and 2 weeks post the second dose

  6. Influenza geometric mean titer fold change

    Increase in Geometric mean titer of spike neutralisation antibodies by primary vaccine group

    Time frame: Between baseline and 2 weeks post the second dose

  7. Safety assessment 1

    Frequency of Adverse events by primary vaccine group

    Time frame: Between time of administration of first dose and through study completion, an average of 10 months

  8. Safety assessment 2

    Frequency of Serious Adverse events by primary vaccine group

    Time frame: Between time of administration of first dose and through study completion, an average of 10 months

  9. SARS-CoV-2 infection

    Frequency of SARS-CoV-2 infections in study participants by primary vaccine group, age, gender, co-morbidities, and past infection

    Time frame: From 2 weeks post the administration of the second dose and through study completion, an average of 10 months

  10. Influenza infection

    Frequency ofinfluenza infections in study participants by primary vaccine group, age, gender, co-morbidities, and past infection

    Time frame: From 2 weeks post the administration of the second dose and through study completion, an average of 10 months

Secondary outcomes

  1. Antibody durability

    The proportion of subjects who remain seroprotected throughout the duration of the study including broken down by primary vaccine group.

    Time frame: From 2 weeks post the administration of the second dose and through study completion, an average of 10 months

  2. Seroconversion in participants with and without evidence of past infection

    Antibody seroconversion in participants by primary vaccine group

    Time frame: From 2 weeks post the administration of the second dose and through study completion, an average of 10 months

  3. Antibody GMT in participants with and without evidence of past infection

    Antibody GMT in baseline seropositive versus negative participants by primary vaccine group.

    Time frame: From 2 weeks post the administration of the second dose and through study completion, an average of 10 months

  4. Antibody correlates of protection

    antibody levels in subjects with or without breakthrough infection

    Time frame: From 2 weeks post the administration of the second dose and through study completion, an average of 10 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — There is no plan to share IPD with external researchers

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2024 (actual). Primary completion is estimated for Dec 2025, 19 months after the start.

Of 233 industry-sponsored phase 1 interventional studies under COVID-19, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 12. This study's planned 19 months is above that.

Counting every sponsor, half of 384 studies reached it within 7 months; a quarter within 3 and three quarters within 15.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 7, 2024
First posted
Apr 9, 2024
StartActual
May 1, 2024
Primary completionEst.
Dec 31, 2025
CompletionEst.
Dec 31, 2026
Last update
Sep 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06355232
Lead sponsor
Vaxine Pty Ltd
Collaborators
Australian Respiratory and Sleep Medicine Institute
Responsible party
Sponsor
First posted
Apr 9, 2024
Start date
May 1, 2024
Primary completion
Dec 31, 2025 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Sep 17, 2025

Study contacts

Sharen Pringle, GradCert
Contact
office@arasmi.org
0437033400
Dimitar Sajkov, MBBS/PhD
principal investigator · ARASMI

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion